Tech Company Financing Transactions

ORIC Pharmaceuticals Funding Round

EcoR1 Capital Management, Foresite Capital and OrbiMed joined a $53 million Series B venture round for ORIC Pharmaceuticals. The round was recorded on 12/3/2015.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series B
Proceeds Purpose
The funds will be used to support advancement of the company's first drug candidate into initial clinical trials and to further develop the company's pipeline.

Company Information

Company Status
Mailing Address
240 E. Grand Ave. 2nd Floor
South San Francisco, CA 94080
Email Address
ORIC Pharmaceuticals Nasdaq: ORIC) is dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs.
ORIC Pharmaceuticals LinkedIn Company Profile
Social Media
ORIC Pharmaceuticals Company Twitter Account
Company News
ORIC Pharmaceuticals News
ORIC Pharmaceuticals on Facebook
ORIC Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Jacob Chacko
  Jacob Chacko LinkedIn Profile  Jacob Chacko Twitter Account  Jacob Chacko News  Jacob Chacko on Facebook
Chief Financial Officer
Dominic Piscitelli
  Dominic Piscitelli LinkedIn Profile  Dominic Piscitelli Twitter Account  Dominic Piscitelli News  Dominic Piscitelli on Facebook
Chief Medical Officer
Pratik Multani
  Pratik Multani LinkedIn Profile  Pratik Multani Twitter Account  Pratik Multani News  Pratik Multani on Facebook
Chief Scientific Officer
Lori Friedman
  Lori Friedman LinkedIn Profile  Lori Friedman Twitter Account  Lori Friedman News  Lori Friedman on Facebook
Vice President
Edna Maneval
  Edna Maneval LinkedIn Profile  Edna Maneval Twitter Account  Edna Maneval News  Edna Maneval on Facebook
VP - Bus. Development
Matthew Panuwat
  Matthew Panuwat LinkedIn Profile  Matthew Panuwat Twitter Account  Matthew Panuwat News  Matthew Panuwat on Facebook
VP - General Counsel
Christian Kuhlen
  Christian Kuhlen LinkedIn Profile  Christian Kuhlen Twitter Account  Christian Kuhlen News  Christian Kuhlen on Facebook



Browse more venture capital transactions:

Prev: 12/3/2015: Figma venture capital transaction
Next: 12/4/2015: Icon Bioscience venture capital transaction


Share this article


Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary